China requires generics to obtain brand-name drug quality

Pharmaceutical companies in China have been ordered to make sure the quality and efficacy of their generics are on par with brand-name drugs, a move that aims to improve the nation's pharma industry, reports the state news agency Xinhua.

According to a circular issued by the State Council General Office, generic drugs already available on the market should be assessed on whether they are consistent with brand-name drugs, and if they could be used clinically. The assessment should be in-house, and the drug watchdog will publicize those medicines that passed the assessment, the circular said.

The government will also include drugs in the national insurance program if they pass the assessment and public hospitals will prioritize these drugs in procurement, among other favorable policies.